CeriBell, Inc. is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining highly portable and rapidly deployable hardware with artificial intelligence-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared (510(k)) for indicating suspected seizure activity and utilized in intensive care units and emergency rooms across the United States. Clarity, its machine learning algorithm, continuously interprets a patient’s EEG waveforms and displays actionable insights regarding seizure activity on the recorder. Its EEG portal is a cloud-based portal that enables real-time remote access to a patient’s EEG data.
높은 성장
회사의 매출은 지난 3년간 꾸준히 성장해왔으며, 연평균 152.47%의 증가율을 기록했습니다.
성장 중
회사는 성장 단계에 있으며, 최신 연간 수익은 미화 65.44M에 달합니다.
공정한 가치
회사의 최신 PE은 -15.13로, 최근 3년 기준 중간 백분위 범위에 속합니다.
기관 매도
최신 기관 보유 주식 수는 30.92M주이며, 전 분기 대비 0.09% 감소했습니다.
PRFDX가 보유
스타 투자자 PRFDX이(가) 이 주식 2.34K주를 보유하고 있습니다.